
Claims

1. Use of an antibody-drug conjugate in the manufacture of a medicament for treating a metastatic brain tumor,

wherein the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula is conjugated to an antibody via a thioether bond:



wherein A represents a connecting position to ~~an~~ the antibody~~;~~

~~is conjugated to the antibody via a thioether bond~~;

and wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2, or

wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of an amino acid

sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

2. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is at least one selected from the group consisting of breast cancer, lung cancer, melanoma, renal cell cancer, kidney cancer, colorectal cancer, gastric cancer, head and neck cancer, hepatocellular cancer, liver cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic cancer, endometrial cancer, thyroid cancer, malignant lymphoma and sarcoma.

3. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is at least one selected from the group consisting of breast cancer, lung cancer and melanoma.

4. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is breast cancer.

5. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is lung cancer.

6. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is melanoma.

7. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is gastric cancer.

8. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is colorectal cancer.

9. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is bladder cancer.

10. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is sarcoma.

~~7. Use according to any one of claims 1 to 6, wherein the antibody is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody.~~

~~8. Use according to claim 7, wherein the antibody is an anti-HER2 antibody.~~

~~9~~11. Use according to any one of claims ~~8~~1 to 10, wherein the anti-HER2 antibody comprises a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

~~10~~12. Use according to any one of claims ~~8~~1 to 10, wherein the anti-HER2 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

~~11~~13. Use according to any one of claims ~~8~~ 1 to ~~10~~12, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

~~12. Use according to claim 7, wherein the antibody is an anti-HER3 antibody.~~

~~13. Use according to claim 12, wherein the anti-HER3 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~14. Use according to claim 12, wherein the anti-HER3 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 in which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~15. Use according to any one of claims 12 to 14, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~16. Use according to claim 7, wherein the antibody is an anti-TROP2 antibody.~~

~~17. Use according to claim 16, wherein the anti-TROP2 antibody comprises a heavy chain consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~18. Use according to claim 16, wherein the anti-TROP2 antibody comprises a heavy chain consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 in which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~19. Use according to any one of claims 16 to 18, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~20. Use according to claim 7, wherein the antibody is an anti-B7-H3 antibody.~~

~~21. Use according to claim 20, wherein the anti-B7-H3 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~22. Use according to claim 20, wherein the anti-B7-H3 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 from which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~23. Use according to any one of claims 20 to 22, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~24. Use according to claim 7, wherein the antibody is an anti-GPR20 antibody.~~

~~25. Use according to claim 24, wherein the anti-GPR20 antibody comprises a heavy chain consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain~~

~~consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~26. Use according to claim 24, wherein the anti-GPR20 antibody comprises a heavy chain consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 from which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~27. Use according to any one of claims 24 to 26, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~28. Use according to claim 7, wherein the antibody is an anti-CDH6 antibody.~~

~~29. Use according to claim 28, wherein the anti-CDH6 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~30. Use according to claim 28, wherein the anti-CDH6 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 from which a lysine~~

~~residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~31. Use according to any one of claims 28 to 30, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~